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Late effectsand 24 months for children and adults, respectively. A myeloablative preparative regimen was used in the
second transplantation in 62% of children and 45% of adult patients. The overall 10-year conditional survival
rates after second transplantation in this cohort of patients who had survived disease-free for at least 1 year
was 55% in children and 39% in adults. Relapse was the leading cause of mortality (77% and 54% of deaths in
children and adults, respectively). In multivariate analyses, only disease status before second HCT was
signiﬁcantly associated with higher risk for overall mortality (hazard ratio, 1.71 for patients with disease not
in complete remission before second HCT, P < .01). Chronic graft-versus-host disease (GVHD) developed in
43% and 75% of children and adults after second transplantation. Chronic GVHD was the leading cause of
nonrelapse mortality, followed by organ failure and infection. The cumulative incidence of developing at least
1 of the studied late effects within 10 years after second HCT was 63% in children and 55% in adults. The most
frequent late effects in children were growth disturbance (10-year cumulative incidence, 22%) and cataracts
(20%); in adults they were cataracts (20%) and avascular necrosis (13%). Among patients with acute leukemia
and myelodysplastic syndromes who receive a second allogeneic HCT for relapse and survive disease free for
at least 1 year, many can be expected to survive long term. However, they continue to be at risk for relapse
and nonrelapse morbidity and mortality. Novel approaches are needed to minimize relapse risk and long-
term transplantation morbidity in this population.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Disease relapse is the leading cause of treatment failure
after allogeneic hematopoietic cell transplantation (HCT) for
hematologic malignancy and occurs in approximately 20% to
60% of patients [1-5]. The outcome after disease relapse after
ﬁrst transplantation is poor, with survival rates less than 10%
in somepopulations, and treatment options for these patients
are limited [5-8]. Second HCT is a potentially curative option
for selected patients and disease relapse is the most common
indication for second allogeneic transplantation [9]. The de-
cision to undergo a second transplantation is complex, given
the heightened risks of disease recurrence, acute toxicity,
post-transplantation late effects, and transplantation-related
mortality.
Rates of overall survival after second allogeneic HCT range
between 28% and 60%, with disease-free survival rates of 25%
to 56% [1,2,9-15]. Studies of second transplantation in chil-
dren have demonstrated more favorable survival, but are
limited by small patient numbers [11,16]. Previous studies of
second transplantation have been limited in sample size and,
hence, have been inconsistent in identifying favorable factors
for longer survival after second allogeneic HCT. Notwith-
standing the limitation of small sample size, factors associ-
ated with superior survival include younger recipient age,
longer duration of remission between transplantations,
complete remission (CR) at second transplantation, bone
marrow as the stem cell source, the use of a fully HLA-
matched donor, the presence of acute and chronic graft-
versus-host disease (GVHD), and transplant from a female
donor [1,9-12,17,18]. An area of controversy has been the
impact of the intensity of conditioning regimen on survival,
as some studies have found reduced-intensity conditioning
regimens to favorably impact survival, whereas others found
survival to beneﬁt from high-dose myeloablative regimens
containing total body irradiation [2,12,15]. An additional area
of discussion is the impact of using the same or alternate
donor with the second transplantation.
Much attention has been paid to analyzing late effects
after single allogeneic HCT. The Bone Marrow Transplant
Survivor Study reported that 66% to 79% of long-term sur-
vivors of HCT suffered from at least 1 chronic health condi-
tion [19-21]. The rates of long-term survival and the
incidence of late effects after second allogeneic trans-
plantation have not been well described. Given the cumu-
lative exposure to chemotherapy and radiation, recipients of2 or more transplants may be at substantial risk for late
complications.
In this study, we selected a cohort of patients who were
alive and in remission for 1 year or more after a second
allogeneic HCT for relapsed acute leukemia or myelodys-
plastic syndrome (MDS) to describe: (1) long-term survival
and predictive factors for survival outcomes, and (2) cumu-
lative incidence of late effects in this population.
MATERIALS AND METHODS
Data Source and Patients
Data for this study were obtained from the Center for International
Blood and Marrow Transplant Research (CIBMTR). The CIBMTR is a volun-
tary working group of more than 450 transplantation centers worldwide
that contribute detailed data on hematopoietic cell transplantations to a
statistical center at the Medical College of Wisconsin in Milwaukee and the
National Marrow Donor Program in Minneapolis. Participating centers are
required to report all transplantation consecutively; compliance is moni-
tored by on-site audits. Patients are followed longitudinally. Computerized
checks for discrepancies, physicians’ review of submitted data, and on-site
audits of participating centers ensure data quality. Data are collected
before transplantation, 100 days and 6 months after transplantation, and
annually thereafter, or until death. Observational studies conducted by the
CIBMTR are performed under guidance of the institutional review board of
the National Marrow Donor Program and are in compliance with all appli-
cable federal regulations pertaining to the protection of human research
participants.
Transplantation-essential data are collected for all patients participating
in CIBMTR data collection. These includes demographic, disease type and
stage, survival, relapse, graft type, the presence of GVHD, and cause of death
data. A subset of CIBMTR participants are selected for comprehensive
research level data collection by weighted randomization. Late effects data
are collected from this group of patients. Transplantation centers report the
presence of clinically signiﬁcant organ impairment or disorder at 6 months
and 1 year after transplantation and annually thereafter. Centers are spe-
ciﬁcally asked to report the presence of the following late effects: stroke/
seizure, myocardial infarction, cirrhosis, gonadal dysfunction requiring
hormone replacement, renal failure severe enough to warrant dialysis,
avascular necrosis, cataracts, growth hormone deﬁciency/growth distur-
bance, hypothyroidism, and bronchiolitis obliterans.
Study Population
The study population included children (age 18 years) and adults (age
> 18 years) who had survived disease free for at least 1 year after their
second allogeneic HCT for acute lymphoblastic leukemia, acute myeloge-
nous leukemia, juvenile myelomonocytic leukemia (JMML), and MDS be-
tween January 1,1980 and December 31, 2009. Therewas no exclusion based
on type of conditioning regimen. The intensity of the conditioning regimen
was based on the deﬁnitions published by Bacigalupo et al. [22]. All types of
donor grafts were included with the exception of syngeneic twins. Patients
who had an allogeneic HCT after autologous transplantation were not
included in the analysis.
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patients with acute lymphoblastic leukemia, acute myelogenous leukemia,
JMML, and MDS during the study time period, 1285 (63%) transplantation
were performed for disease relapse. Other indications for second HCT were
nonengraftment or graft failure (31%) and newmalignancy (1%). The reason
for second transplantation was unknown for 5% of the population. Among
those who underwent transplantation for disease relapse, 952 (74%) pa-
tients died or experienced disease relapse in the ﬁrst year after the second
transplantation. From the 333 remaining patients, 8 were further excludedTable 1
Patient and Transplantation Characteristics
Characteristics at Second HCT
No. of patients
No. of centers
Male/female
Disease
Acute myeloid leukemia
Acute lymphoblastic leukemia
MDS
JMML
Patient age at ﬁrst transplantation, median (range), yr
Patient age at second transplantation, median (range), yr
Lansky/Karnofsky score  90
Donor type
HLA-matched sibling
Other related
Unrelated
Graft type
Bone marrow
Peripheral blood stem cells
Umbilical cord blood
Disease status before ﬁrst HCT*
Early
Intermediate
Advanced
Unknown
Disease remission status before second HCT
Complete remission
Relapse/progression
Unknown
Interval from ﬁrst HCT to relapse, median (range), mo
<12 months
12-23 months
24 months
Interval from ﬁrst HCT to second HCT, median (range), mo
<12 months
12-23 months
24 months
First HCT and second HCT donor pair
Same related donor
Different related donor
Related donor e unrelated donor
Related donor e donor relationship unknown
Same unrelated donor
Different unrelated donor
Unrelated donor e related donor
Unrelated, donor e donor relationship unknown
Conditioning regimen intensity for ﬁrst HCT
Myeloablative
Reduced intensity
Conditioning regimen intensity for second HCT
Myeloablative
Reduced intensity
None
Unknown
Year of second HCT
1980-1989
1990-1999
2000-2009
* Disease status classiﬁcation: early-risk disease included acute leukemia in ﬁrs
fractory anemia with ringed sideroblasts, or unspeciﬁed myelodysplastic syndro
included acute leukemia in second or greater complete remission; advanced-risk
myelodysplastic syndrome, refractory anemia with excess blasts or excess blast
leukemia.because of an unknown graft type. The ﬁnal study cohort consisted of 325
second transplant recipients who had survived in remission for at least 1
year after the second transplantation.Statistical Analysis
Descriptive statistics were used to describe patient demographic,
disease, and HCT-related variables. All outcomes were evaluated, unless
clariﬁed, by calculating the probability of that outcome after secondAge at Second Transplantation
Children (18 years) n (%) Adults (>18 years) n (%)
146 179
71 92
92 (63)/54 (37) 99 (55)/80 (45)
64 (44) 111 (62)
66 (45) 54 (30)
12 (8) 14 (8)
4 (3) 0
7 (<1-16) 35 (14-66)
9 (1-17) 38 (19-66)
101 (69) 96 (54)
78 (53) 99 (55)
8 (5) 8 (4)
60 (41) 72 (40)
94 (64) 63 (35)
34 (23) 113 (63)
18 (12) 3 (2)
67 (46) 90 (50)
49 (34) 35 (20)
26 (18) 54 (30)
4 (3) 0
108 (74) 88 (49)
29 (20) 77 (43)
9 (6) 14 (8)
14 (<1-145) 18 (<1-157)
67 (46) 64 (36)
42 (29) 44 (25)
37 (25) 71 (40)
17 (2-149) 24 (2-158)
46 (32) 41 (23)
48 (33) 49 (27)
52 (36) 89 (50)
72 (50) 80 (45)
8 (6) 21 (12)
9 (6) 7 (4)
4 (2) 3 (2)
15 (10) 26 (15)
27 (18) 33 (18)
3 (2) 3 (2)
9 (6) 6 (3)
130 (89) 141 (79)
5 (3) 33 (18)
90 (62) 81 (45)
38 (26) 73 (41)
5 (3) 12 (7)
5 (3) 12 (7)
14 (10) 20 (11)
67 (45) 53 (30)
65 (45) 106 (59)
t complete remission, myelodysplastic syndrome, refractory anemia, or re-
me with pretransplantation marrow blasts <5%; intermediate-risk disease
disease included acute leukemia in relapse or primary induction failure,
s in transformation or marrow blasts >5%, and juvenile myelomonocytic
Table 2
Conditional Probability of Overall Survival and Cumulative Incidence of
Nonrelapse Mortality and Relapse among One-Year Disease-Free Survivors
after Second Allogeneic Hematopoietic Cell Transplantation
Outcomes Children Adults
Patients
at Risk
% (95% CI) Patients
at Risk
% (95% CI)
Relapse
2 Years 105 21 (15-28) 118 15 (10-20)
6 Years 47 34 (26-43) 49 27 (21-35)
10 Years 19 34 (26-43) 18 32 (24-40)
Nonrelapse mortality
2 Years 105 4 (2-8) 118 15 (10-21)
6 Years 47 8 (4-14) 49 27 (20-34)
10 Years 19 10 (5-17) 18 34 (26-42)
Overall survival
2 Years 118 83 (77-89) 133 75 (69-81)
6 Years 52 64 (55-72) 55 51 (43-58)
10 Years 18 55 (44-65) 22 39 (31-48)
95% CI indicates 95% conﬁdence interval.
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and remained disease free for at least 1 year after the second trans-
plantation. The Kaplan-Meier method was used to estimate the proba-
bility of survival. The cumulative incidence function was used to estimate
relapse-related death, nonrelapse mortality, and late effects. Rates of in-
dividual late effects occurring between the ﬁrst and second HCT were
calculated. Rates of individual late effects were calculated after ﬁrst HCT
(censored at second transplantation). Cumulative incidences of late effects
and probabilities of other outcomes were estimated for 2 and 10 years
after the second HCT and are reported separately for children and adult
survivors. A proportional hazards model was developed to assess risk
factors for the conditional risk of overall mortality among the study
population. Potential risk factors considered include age, separately
among children and adults as well as children versus adults, diagnosis
category, disease status at ﬁrst and second transplantation (CR versus
relapse/progressive disease/partial remission), ﬁrst-second trans-
plantation donor pair (related-related versus related-unrelated versus
unrelated-unrelated, same donor versus unrelated-unrelated, different
donor versus other), development of GVHD before second transplantation
(none versus acute GVHD alone versus acute GVHD and chronic GVHD),
interval between ﬁrst and second transplantations, and conditioning in-
tensity at second transplantation (myeloablative versus non-
myeloablative/reduced intensity). Patients with JMML were excluded
from the proportional hazard model because of small patient numbers.
Proportional hazards models were not developed to assess risk factors for
late effects because of sample size limitations. Analyses were performed
using SAS, version 9.3 (SAS Institute, Cary, NC).RESULTS
Patient and Transplantation Characteristics
Patient and transplantation characteristics are presented
in Table 1. Of the 325 patients eligible for analysis, 146 were
children and 179 were adults. The median interval between
the ﬁrst and second transplantation was 17 months (range, 2
to 149 months) and 24 months (range, 2 to 158 months) for
children and adults, respectively. The majority of children
(74%) were in CR before second HCT, compared with 49% of
adults. Children received a myeloablative conditioning
regimen in 89% of ﬁrst and 62% of second transplantations.
The corresponding values for adults were 79% of ﬁrst and 45%
of second transplantations. Of those who received a mye-
loablative regimen in the ﬁrst HCT, 61% of children and 44%
of adults had a myeloablative regimen with second trans-
plantation. Total body irradiation was used in the condi-
tioning regimen in 45% of ﬁrst and 40% of second pediatric
and in 55% and 25% of adult transplantations. No condi-
tioning agent or radiation was used with the second trans-
plantation in 3% of children and 7% of adult patients. The
median follow-up after second transplantation among both
children and adult survivors was 72 months (range, 17 to 219
and 12 to 288 months, respectively).Figure 1. Overall survival among 1-year disease-free survivors of second
allogeneic transplantation for acute myeloid leukemia, acute lymphoblastic
leukemia, JMML, and MDS: (A) adult patients (age 18 years at second
transplantation), and (B) children (age <18 years at second transplantation).Survival, Nonrelapse Mortality, and Relapse Outcomes
Among the 1-year survivors included in our study, 2- and
10-year conditional survival rates were 83% (95% conﬁdence
interval [CI], 77% to 89%) and 55% (95% CI, 44% to 65%) among
children and 75% (95% CI, 69% to 81%) and 39% (95% CI, 31% to
48%) among adults (Table 2, Figure 1). Cumulative incidence
of nonrelapse mortality among children was 4% and 10% at 2
years and 10 years, respectively (Table 2, Figure 2). The cor-
responding ﬁgures among adults were 15% and 34%,
respectively. The cumulative incidence of relapse at 2 years
and 10 years was 21% and 34% in children and 15% and 32% in
adults, respectively (Table 2, Figure 3). Disease progression or
relapse was the major cause of death (43 of 56 [77%] for
children and 52 of 96 [54%] for adults). Overall causes of
nonrelapse mortality included GVHD (32%), organ failure
(25%), infection (16%), secondarymalignancy (5%), and other/
unknown cause (23%). The leading causes of nonrelapsemortality in childrenwere GVHD (5%), organ failure (5%), and
secondarymalignancy (4%). The leading causes of nonrelapse
mortality in adult patients were GVHD (16%), organ failure
(11%), and infection (9%).
In proportional hazard models, disease status at the time
of second HCTwas the only independent predictor for overall
mortality. The overall survival at 5 years for patients who
were in CR at the time of the second transplantationwas 66%
(95% CI, 59% to 73%) compared with 48% (95% CI, 38% to 58%)
for those not in remission at the time of transplantation.
Comparedwith patients whowere in CR, patients with active
disease had signiﬁcantly higher risks for overall mortality
(hazard ratio, 1.71; 95% CI, 1.22 to 2.38; P ¼ .0017).
Figure 3. Relapse among 1-year disease-free survivors of second allogeneic
transplantation for acute myeloid leukemia, acute lymphoblastic leukemia,
JMML and MDS: (A) adult patients (age 18 years at second transplantation),
and (B) children (age <18 years at second transplantation).
Figure 2. Nonrelapse mortality among 1-year disease-free survivors of second
allogeneic transplantation for acute myeloid leukemia, acute lymphoblastic
leukemia, JMML and MDS: (A) adult patients (age 18 years at second
transplantation), and (B) children (age <18 years at second transplantation).
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Between ﬁrst and second allogeneic HCT, at least 1 late
effect was reported in 12% of patients. The most common
reported late effects in children were stroke/seizures (3%)
and growth disturbance (3%). Gonadal dysfunction (5%) and
cataracts (5%) were the most frequently reported late effects
among adults. Grade 2 to 4 acute GVHD was reported after
the ﬁrst allogeneic transplantation in 30% of children and
26% of adults. Grade 2 to 4 acute GVHD was diagnosed after
the second transplantation in 47% of children and 46% of
adults. Chronic GVHD requiring treatment was reported
before the second transplantation in 16% and 32% of children
and adults, respectively. New onset chronic GVHD requiring
treatment was diagnosed after the second transplantation in
43% of children and 75% of adults. Data regarding the status
or severity of chronic GVHD are not uniformly reported by
centers to the CIBMTR database and these data are not
presented.
The cumulative incidence of developing any late effect at
2 years and 10 years after second HCTwas 42% (95% CI, 32% to
52%) and 63% (95% CI, 53% to 73%) among children and 45%
(95% CI, 36% to 54%) and 55% (95% CI, 46% to 64%) among
adults, respectively. The cumulative incidences of speciﬁc
late effects are reported in Table 3. Ten years after second
transplantation, the incidence was >10% for gonadal
dysfunction, cataracts, growth hormone deﬁciency/growth
disturbance, and hypothyroidism in pediatric survivors. Only
avascular necrosis and cataracts were reported with an
incidence greater than 10% in adult survivors. The 10-year
cumulative incidence of a second cancer after second trans-
plantation was 1% (95% CI, 0 to 4%) in pediatric and 8% (95%
CI, 4% to 13%) in adult survivors. The primary sites for second
cancers included nonmelanoma skin cancer (n ¼ 9), oral
cavity (n ¼ 2), sarcoma (n ¼ 2), skin melanoma (n ¼ 1), and
gastrointestinal tract (n ¼ 1). In addition, 1 patient had post-
transplantation lymphoproliferative disorder and 2 patients
were reported to have squamous cell cancers of unknown
site (the primary site could not be conﬁrmed by the trans-
plantation center).
DISCUSSION
In the present era, with several advances in post-
transplantation supportive care practices, it is not unusual
for a second allogeneic transplantation to be considered as
treatment for patients whose disease relapses or progresses
after a ﬁrst allogeneic transplantation. We present the out-
comes of a relatively large cohort of patients reported to the
CIBMTRwho received a second allogeneic transplantation for
disease relapse and had survived in remission for at least 1
year. By focusing on long-term survival and late effects in this
population, our study addresses important gaps in the liter-
ature. Our ﬁndings will inform the medical decision making
of transplantation providers as they consider a second allo-
geneic transplantation in patients with relapsed acute leu-
kemia and MDS.
There were several key ﬁndings in our analysis. First, we
show that the majority of recipients of second allogeneic
transplantations relapsed or died within the ﬁrst year (74% in
our study), conﬁrming earlier results from smaller studies
[1,2,15,23,24]. Second, we have shown that disease status at
the time of second transplantation was the most important
predictor of subsequent long-term survival. Patients in CR at
the time of second transplantation had higher survival
chances than those who were not in CR. Also, although
considering the very high-risk nature of their disease, a
Table 3
Late Effects among One-Year Disease-Free Survivors after Second Allogeneic Hematopoietic Cell Transplantation
Patient and Transplantation Characteristics Age Group at Second Transplantation
Children (18 years) Adults (>18 years)
Rate before
Second HCT* n (%)
CI at 2 yearsy
% (95% CI)
CI at 10 yearsy
% (95% CI)
Rate before
Second HCT*
n (%)
CI at 2 yearsy
% (95% CI)
CI at 10 yearsy
% (95% CI)
Seizure/stroke 4 (3) 4 (1-7) 4 (2-8) 2 (1) 0 1 (0-2)
Myocardial infarction 0 0 0 0 1 (0-2) 1 (0-2)
Gonadal dysfunction 3 (2) 6 (3-11) 16 (10-23) 9 (5) 4 (2-7) 5 (2-8)
Renal failure 1 (1) 1 (0-4) 4 (1-8) 2 (1) 3 (1-6) 4 (1-7)
Avascular necrosis 2 (1) 4 (2-8) 5 (2-9) 4 (2) 10 (6-15) 13 (9-19)
Cataracts 1 (1) 9 (4-14) 20 (13-28) 9 (5) 14 (9-20) 20 (14-26)
Growth hormone deﬁciency/growth failure 4 (3) 8 (4-14) 22 (15-30) 0 0 0
Hypothyroidism 1 (1) 7 (3-12) 13 (7-20) 2 (1) 2 (1-5) 4 (1-7)
Cirrhosis 0 0 0 0 0 0
Bronchiolitis obliterans 0 3 (1-7) 4 (1-8) 1 (1) 4 (2-8) 4 (2-8)
Second cancers 0 1 (0-3) 1 (0-4) 2 (1) 1 (0-3) 8 (4-13)
CI indicates cumulative incidence.
* Rate of late effects after ﬁrst allogeneic transplantation, but before second transplantation (censored at time of second transplantation).
y Cumulative incidence estimates.
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free at 1 year after their second transplantation continued to
survive on long-term (up to 10 years) follow-up. However,
relapse continued to be the major cause of treatment failure,
even among the disease-free survivors beyond the ﬁrst year
after second transplantation. Finally, a relatively large pro-
portion of second transplantation survivors suffered from
long-term toxicities.
Overall survival for patients who survived the ﬁrst year
after their second transplantation was favorable at 2 years
(83% in children and 75% in adults). Overall survival gradually
declined before stabilizing between years 7 and 8 with
overall survival at 10 years of 55% in children and 39% in
adults. Disease relapse or progression was the leading cause
of mortality after second transplantation and accounted for
77% and 52% of deaths in children and adults, respectively.
This is consistent with the published literature of all patients
after second HCT [1,9,15,17,25]. As expected, nonrelapse
mortality rates were generally lower for children compared
with for adults [1,9,15,25].
Disease status in remission and longer duration between
ﬁrst transplantation and relapse and second HCT are the
most consistent factors inﬂuencing survival after second HCT
across multiple studies [3,5,11,15,17,26]. We evaluated these
factors, as well as other published potential prognostic fac-
tors, including diagnosis, patient age, disease status at ﬁrst
HCT, donor pairing at ﬁrst and second HCT, GVHD after ﬁrst
transplantation, and conditioning intensity at second HCT [1-
3,9,24,27,28]. Stem cell source was not evaluated as there
were insufﬁcient patients in each group to draw conclusions.
Remission status was the only factor predictive of survival
after second transplantation in our study. Similar to other
studies, patients in CR had a survival advantage compared
with those who underwent transplantation with active dis-
ease [15,17,24,26,29]. This ﬁnding supports the use of addi-
tional therapy, if feasible, to achieve CR before second HCT
for patients with relapsed acute leukemia and MDS to
maximize the potential for long-term survival. Patients with
disease relapse after a ﬁrst allogeneic HCT should be
encouraged to participate in clinical trials of novel treatment
approaches [30].
We did not ﬁnd an association of donor switching be-
tween ﬁrst and second transplantation and overall survival.
This may be explained by the relatively small number ofdonor-recipient pairs in each of the groups analyzed
(related-related versus related-unrelated versus unrelated-
unrelated [same donor] versus unrelated-unrelated
[different donor] versus other). Some prior investigations
were similarly restricted in their ability to detect a survival
difference attributable to change in donor pairing due to
limited sample size. However, the results of this and prior
studies do not support the strategy of changing donors be-
tween ﬁrst and second transplantation in an effort to
improve overall survival [1,2,11,15,25]. When comparing the
results of our study with published literature, it is worth
noting that survival and risk factor analyses in prior studies
included all patients, regardless of survival since trans-
plantation, whereas we focused only on those who survived
disease free for the initial post-transplantation year. Thismay
explain why the time between ﬁrst and second HCT was not
predictive of survival, as patients with shorter duration be-
tween transplantations may have relapsed or died during the
ﬁrst year.
We report the cumulative incidence of developing at least
a single late effect at 10 years after second HCT of 63% in
children and 55% in adult patients. The cumulative incidence
of late effects between 2 and 10 years did not increase sub-
stantially in adults. The increase in the cumulative incidence
of late effects in children between 2 and 10 years was pri-
marily due to gonadal failure. The median age of 9 years
indicates that many of the patients were prepubertal at the
time of second transplantation. The cumulative incidences of
late effects presented are similar to what is described in the
literature in long-term survivors of single transplantation.
Patients in the Bone Marrow Transplant Survivor Study re-
ported at least 1 chronic health condition in 32% to 38.2% of
2-year survivors and in 74% of 10-year survivors of ﬁrst
transplantation for leukemia and aplastic anemia [20,21,31].
This is also comparable to the 79% of 145 pediatric survivors
of single transplantation followed for a median of 11 years
and lower than the 91% found in 99 Australian patients fol-
lowed for a median of 74 months after ﬁrst HCT [19,32]. The
speciﬁc late effects evaluated differ in each of the studies
referenced. However, the categories of conditions investi-
gated are similar and reasonably allow for comparison be-
tween studies. CIBMTR data forms capture a limited number
of late complications, and hence, we may have under-
estimated the true incidence of late effects in second
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emphasizes the need for continued long-term surveillance
for late effects in this population [33,34].
We acknowledge several limitations to our retrospective
cohort study. First, there is the potential for selection bias at
the level of the individual centers regarding which patients
are offered a second transplantation (eg, patients may be
more likely to receive a second transplantation if they have
fewer comorbidities, better performance status, absence of
severe GVHD, and longer time between ﬁrst transplantation
and relapse). As noted above, data were collected on selected
late effects. Capture of long-term follow-up information by
transplantation centers for their transplant recipients can be
challenging. However, our follow-up information was robust
with a completeness index of follow-up (ratio of observed
versus expected follow-up for the cohort) of 94% at 5 years
and 83% at 10 years after second transplantation. Screening
practices can differ between institutions, resulting in po-
tential under-reporting of speciﬁc effects. The median
follow-up of our cohort was approximately 6 years. Although
this is an acceptable period of time, it is possible that a longer
duration of follow-up may result in an increase in the
number of reported late effects. Finally, even though our
study is the largest to date, the number of patients included
and the number of post-transplantation events were still
relatively small and future studies will have to readdress this
issue in larger patient cohorts. On the same note, the number
of umbilical cord blood recipients was small and outcomes
with second transplantations using this graft source will
have to be characterized in larger studies.
In summary, the 1-year overall survival after second
allogeneic transplantation for relapsed acute leukemia and
MDS is suboptimal. However, many patients who live
disease-free for at least 1 year after second transplantation
can be expected to survive long term and their survival is
best optimized when patients receive a second trans-
plantationwhile in CR. Themajority of late failures are due to
relapse and late effects are frequently encountered. Future
trials focusing on reducing risks of relapse, novel treatments
for treating post-transplantation relapse, and implementing
systematic surveillance for long-term toxicities in this pop-
ulation are warranted.
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